Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. more
Time Frame | AKRO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.4% | -3.39% | -3.47% |
1-Month Return | -2.88% | -3.25% | -0.29% |
3-Month Return | 6.49% | -11.61% | 4.5% |
6-Month Return | 29.56% | -5.89% | 6.91% |
1-Year Return | 30.56% | 2.65% | 23.79% |
3-Year Return | 32.98% | 0.56% | 28.43% |
5-Year Return | 47.99% | 34.63% | 83.64% |
10-Year Return | 56.71% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 80.15M | 100.89M | 260.00K | 29.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":79.45,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.26,"profit":true},{"date":"2023-12-31","value":0.03,"profit":true}] |
Gross Profit | - | (80.15M) | (100.89M) | (260.00K) | (29.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8015400000,"profit":false},{"date":"2021-12-31","value":-10088600000,"profit":false},{"date":"2022-12-31","value":-26000000,"profit":false},{"date":"2023-12-31","value":-2900000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 45.65M | 80.15M | 100.89M | 115.16M | 172.87M | [{"date":"2019-12-31","value":26.41,"profit":true},{"date":"2020-12-31","value":46.37,"profit":true},{"date":"2021-12-31","value":58.36,"profit":true},{"date":"2022-12-31","value":66.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (45.65M) | (80.15M) | (100.89M) | (115.16M) | (172.87M) | [{"date":"2019-12-31","value":-4565100000,"profit":false},{"date":"2020-12-31","value":-8015400000,"profit":false},{"date":"2021-12-31","value":-10088600000,"profit":false},{"date":"2022-12-31","value":-11515600000,"profit":false},{"date":"2023-12-31","value":-17287000000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | 218.00K | 2.38M | 18.55M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":1.18,"profit":true},{"date":"2022-12-31","value":12.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (43.76M) | (79.21M) | (100.78M) | (112.03M) | (151.76M) | [{"date":"2019-12-31","value":-4375500000,"profit":false},{"date":"2020-12-31","value":-7920700000,"profit":false},{"date":"2021-12-31","value":-10077700000,"profit":false},{"date":"2022-12-31","value":-11203300000,"profit":false},{"date":"2023-12-31","value":-15175900000,"profit":false}] |
Income Taxes | (1.90M) | (17.00K) | (41.00K) | (3.12M) | - | [{"date":"2019-12-31","value":-189600000,"profit":false},{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-4100000,"profit":false},{"date":"2022-12-31","value":-312300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | - | (100.74M) | (108.91M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-10073600000,"profit":false},{"date":"2022-12-31","value":-10891000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (43.76M) | (79.21M) | (100.80M) | (111.97M) | (119.63M) | [{"date":"2019-12-31","value":-4375500000,"profit":false},{"date":"2020-12-31","value":-7920700000,"profit":false},{"date":"2021-12-31","value":-10080100000,"profit":false},{"date":"2022-12-31","value":-11196900000,"profit":false},{"date":"2023-12-31","value":-11963200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (43.76M) | (79.19M) | (100.74M) | (108.91M) | (151.76M) | [{"date":"2019-12-31","value":-4375500000,"profit":false},{"date":"2020-12-31","value":-7919000000,"profit":false},{"date":"2021-12-31","value":-10073600000,"profit":false},{"date":"2022-12-31","value":-10891000000,"profit":false},{"date":"2023-12-31","value":-15175900000,"profit":false}] |
EPS (Diluted) | (3.55) | (2.48) | (2.89) | (2.92) | (2.85) | [{"date":"2019-12-31","value":-354.63,"profit":false},{"date":"2020-12-31","value":-248,"profit":false},{"date":"2021-12-31","value":-289,"profit":false},{"date":"2022-12-31","value":-292,"profit":false},{"date":"2023-12-31","value":-285,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AKRO | |
---|---|
Cash Ratio | 16.57 |
Current Ratio | 17.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AKRO | |
---|---|
ROA (LTM) | -23.17% |
ROE (LTM) | -35.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AKRO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AKRO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.76 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Akero Therapeutics Inc (AKRO) share price today is $27.554
Yes, Indians can buy shares of Akero Therapeutics Inc (AKRO) on Vested. To buy Akero Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AKRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Akero Therapeutics Inc (AKRO) via the Vested app. You can start investing in Akero Therapeutics Inc (AKRO) with a minimum investment of $1.
You can invest in shares of Akero Therapeutics Inc (AKRO) via Vested in three simple steps:
The 52-week high price of Akero Therapeutics Inc (AKRO) is $37. The 52-week low price of Akero Therapeutics Inc (AKRO) is $15.32.
The price-to-earnings (P/E) ratio of Akero Therapeutics Inc (AKRO) is
The price-to-book (P/B) ratio of Akero Therapeutics Inc (AKRO) is 2.76
The dividend yield of Akero Therapeutics Inc (AKRO) is 0.00%
The market capitalization of Akero Therapeutics Inc (AKRO) is $2.14B
The stock symbol (or ticker) of Akero Therapeutics Inc is AKRO